Journal of Stroke & Cerebrovascular Diseases
Volume 16, Issue 4 , Pages 153-159 , July 2007

Association of PAI-1 4G/5G and -844G/A Gene Polymorphism and Changes in PAI-1/tPA Levels in Stroke: A Case-Control Study

  • Sarra Saidi, MSc

      Affiliations

    • Research Unit of Hematological and Autoimmune Diseases, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia
    • ,
  • Lamia B. Slamia, MD

      Affiliations

    • Department of Neurology, Centre Hospitalier Universitaire Sahloul, Sousse, Tunisia
    • ,
  • Touhami Mahjoub, PhD

      Affiliations

    • Research Unit of Hematological and Autoimmune Diseases, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia
    • ,
  • Sofyan B. Ammou, MD

      Affiliations

    • Department of Neurology, Centre Hospitalier Universitaire Sahloul, Sousse, Tunisia
    • ,
  • Wassim Y. Almawi, PhD

      Affiliations

    • College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain.
    • Corresponding Author InformationAddress reprint requests to Wassim Y. Almawi, PhD, Department of Medical Biochemistry, College of Medicine and Medical Sciences, Arabian Gulf University, PO Box 22979, Manama, Bahrain.

Received 26 November 2006 ,Revised 18 January 2007 ,Accepted 14 February 2007.

References 

  1. Humphries SE, Morgan L. Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol. 2004;3:227–235
  2. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146:948–957
  3. Eskandari MK, Bontempo FA, Hassett AC, et al. Arterial thromboembolic events in patients with the factor V Leiden mutation. Am J Surg. 1998;176:122–125
  4. Catto AJ, Carter AM, Stickland M, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997;77:730–734
  5. Wiklund PG, Nilsson L, Ardnor SN, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke. 2005;36:1661–1665
  6. Casas JP, Hingorani AD, Bautista LE, et al. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol. 2004;61:1652–1661
  7. Fassbender K, Dempfle CE, Mielke O, et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke. 1999;30:2101–2104
  8. Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke. 2004;35:2123–2127
  9. Haapaniemi E, Soinne L, Syrjala M, et al. Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke. Acta Neurol Scand. 2004;110:242–247
  10. Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol. 2006;4:101–116
  11. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1792–1801
  12. Dobrovolsky AB, Titaeva EV. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc). 2002;67:99–108
  13. Stegnar M, Uhrin P, Peternel P, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998;79:975–979
  14. Ridker PM, Hennekens CH, Stampfer MJ, et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940–943
  15. Kathiresan S, Gabriel SB, Yang Q, et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation. 2005;112:1728–1735
  16. Verschuur M, Jellema A, Bladbjerg EM, et al. The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals. Atherosclerosis. 2005;181:275–284
  17. Grubic N, Stegnar M, Peternel P, et al. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res. 1996;84:431–443
  18. Henry M, Chomiki N, Scarabin PY, et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol. 1997;17:851–858
  19. Festa A, D’Agostino R, Rich SS, et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites (The Insulin Resistance Atherosclerosis Study). Circulation. 2003;107:2422–2427
  20. Bang CO, Park HK, Ahn MY, et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis. 2001;11:294–299
  21. Endler G, Lalouschek W, Exner M, et al. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol. 2000;110:469–471
  22. Hoekstra T, Geleijnse JM, Kluft C, et al. 4G/4G genotype of the PAI-1 gene is associated with reduced risk of stroke in the elderly. Stroke. 2003;34:2822–2828
  23. Johansson L, Jansson JH, Boman K, et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000;31:26–32
  24. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1991;268:10739–10745
  25. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non–insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842–847
  26. Eriksson P, Nilsson L, Karpe F, et al. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18:20–26
  27. Roest M, van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation. 2000;101:67–70
  28. Jood K, Ladenvall P, Tjarnlund-Wolf A, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke. 2005;36:2077–2081
  29. van Goor ML, Garcia EG, Leebeek F, et al. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke: a case-control study. Thromb Haemost. 2005;93:92–96
  30. Hindorff LA, Schwartz SM, Siscovick DS, et al. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk. 2002;9:131–137
  31. Chen CH, Eng HL, Chang CJ, et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med. 2003;142:100–105
  32. Crainich P, Jenny NS, Tang Z, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost. 2003;1:1799–1804
  33. Luttun A, Lupu F, Storkebaum E, et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2002;22:499–505
  34. Rossignol P, Luttun A, Martin-Ventura JL, et al. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost. 2006;4:664–670
  35. Wang X, Tsuji K, Lee SR, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004;35:2726–2730
  36. Strickland S. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost. 2001;86:138–143
  37. Yang Q, Khoury MJ, Botto L, et al. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet. 2003;72:636–649

PII: S1052-3057(07)00036-5

doi: 10.1016/j.jstrokecerebrovasdis.2007.02.002

Journal of Stroke & Cerebrovascular Diseases
Volume 16, Issue 4 , Pages 153-159 , July 2007

Article Tools